AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01934530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Grafting
Description: All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement.
Study NCT03935529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn \& Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, \& Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood.
Study NCT04497506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wise Intervention (Self-affirmation and Incremental theory of personality)
Description: The intervention designed to promote prosocial behavior and reduce online risks is based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes two components: a self-affirmation activity and an ITP intervention. The SA component includes a list of values so that they could choose the two or three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component includes activities such as reading scientific information about social behavior and its role in people's well-being, the meaning and value of online risk behaviors through stories and videos of the experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change.
Study NCT04497506 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard preventive intervention
Description: It consists of an educational intervention that provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
Study NCT03613012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain index
Description: Record the patients' EEG and extract pain index before and after pain treatments
Study NCT00003204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00003204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00003204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00003204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00003204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00003204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00329381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xolair
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Study NCT00329381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Study NCT03051035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KO-947
Description: Intravenous administration
Study NCT01221883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Single dose 10mg Diazepam tablet
Study NCT01221883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam
Description: Single dose 10mg Diazepam tablet
Study NCT03827304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction from Burn Pain
Description: Patients wore a VR headset while undergoing a burns dressing change
Study NCT02069301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Depression/Microfinance Group
Description: LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
Study NCT02069301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: National Guideline for antidepressant care
Study NCT02069301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: National Guideline for antidepressant care
Study NCT02069301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livelihood Support
Description: Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
Study NCT02933125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist.
Study NCT02933125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard supervision
Description: The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:solution Route of administration: subcutaneous injection
Study NCT01678079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Encapsulated Calcium
Description: The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
Study NCT01678079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-capsulated Calcium
Description: The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
Study NCT00367653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Chloroquine
Description: Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
Study NCT00367653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
Study NCT02795741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Bolero
Description: a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
Study NCT01199185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
Study NCT01199185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation plus Weight Loss
Description: All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
Study NCT01823224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 capsules Oral Tylenol 2000 mg and IV salt water
Description: The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly.
Study NCT04158141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04158141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04158141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decortication
Description: Undergo decortication
Study NCT04158141 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04158141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT04158141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT04158141 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning
Description: Undergo PBS
Study NCT04158141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy
Description: Undergo pleurectomy
Study NCT04158141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04158141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01823224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tylenol 1000mg and 2 oral capsule sugar pills
Description: IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group.
Study NCT01627314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProHema-CB
Description: Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT01627314 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Untreated CB
Description: Cord Blood
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Pharmaceutical form:oral suspension Route of administration: oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT03510884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous injection
Study NCT01635101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
Study NCT02646384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian tissue cryopreservation
Description: Ovarian tissue will be removed
Study NCT03945721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring.
Study NCT03945721 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: radiation therapy
Study NCT01635101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Control
Description: IV Control q6h; 4 doses, in 24 hours
Study NCT02034279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Intravenous infusion of 20% albumin
Study NCT02043249 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CORD MILKING
Description: MILKING OF UMBILICAL CORD OF THE BABY
Study NCT02569723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon C 14 Oxaliplatin
Description: Intravenous infusion
Study NCT02569723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenous infusion
Study NCT02814851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiogram
Description: All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
Study NCT02814851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermistor-tipped catheter
Description: All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
Study NCT02814851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure/volume catheter
Description: All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
Study NCT02814851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany).
Study NCT02560584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate hydrochloride
Description: Instillation in bladder
Study NCT02560584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KARL STORZ D-Light C PDD Flexible Videoscope System
Description: Cystoscopy procedure
Study NCT00940420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus (ribavirin)
Description: 800 - 1200 mg po daily for 24 weeks
Study NCT00940420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus (ribavirin)
Description: 800 - 1200 mg po daily for 48 weeks
Study NCT00940420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly for 24 weeks
Study NCT00940420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly for 48 weeks
Study NCT00709046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose pantoprazole infusion
Description: Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
Study NCT00709046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose pantoprazole infusion
Description: Pantoprazole 40mg iv bolus qd x 3 days
Study NCT03618992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cholesterol-containing moisturizers
Description: Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
Study NCT03015012 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Personalized Nutrigenomics Testing (PNT)
Description: Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
Study NCT03015012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Intervention (SNI)
Description: Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.